Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending June 18, 2008. The report details a specific corporate action regarding the company's share repurchase program authorized by shareholders at the Annual General Meeting on May 21, 2008.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The primary financial data relates to the share buyback transaction:
- Shares Purchased: 3,010,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,093.38 pence per share.
- Treasury Shares Held: 474,194,158 shares (representing 8.93% of total voting rights).
- Shares in Issue: 5,311,952,963 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of the company's share capital through the cancellation of 3,010,000 shares purchased on June 18, 2008. This transaction increased the proportion of Treasury shares held by the company to 8.93% of total voting rights.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of specific risks and contingencies. It is a compliance announcement confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer to purchase securities.
Investor Verification Checklist
- Verify the total number of shares in issue (5,311,952,963) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the updated Treasury share count (474,194,158) and its impact on voting rights (8.93%).
- Note that this filing does not contain quarterly or annual financial results; refer to Form 20-F for comprehensive financial data.